https://wikimd.org/index.php?action=history&feed=atom&title=AbagovomabAbagovomab - Revision history2026-05-01T04:17:07ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Abagovomab&diff=2158169&oldid=prevPrab at 22:31, 16 November 20202020-11-16T22:31:49Z<p></p>
<p><b>New page</b></p><div><br />
Abagovomab is a [[monoclonal antibody]] used in the treatment of [[ovarian cancer]]<br />
[[File:Abagovomab.jpg|alt=Abagovomab|thumb|'''Abagovomab''']]<br />
<br />
==Other names==<br />
* ACA 125<br />
* Anti-idiotype ovarian cancer vaccine<br />
* MAb ACA 125<br />
* Monoclonal Anti-idiotype Antibody ACA125<br />
<br />
==Indications==<br />
Abagovomab is studied as an anti-idiotypic [[CA-125]] targeted immunotherapeutic agent for [[ovarian cancer]]<br />
<br />
<youtube><br />
title='''{{PAGENAME}}'''<br />
movie_url=http://www.youtube.com/v/dCwaanccP34<br />
&rel=1<br />
embed_source_url=http://www.youtube.com/v/dCwaanccP34<br />
&rel=1<br />
wrap = yes<br />
width=750<br />
height=600<br />
</youtube><br />
<br />
== Mechanism of action ==<br />
* A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen [[CA-125]], with potential [[antineoplastic]] activity. <br />
* With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host [[immune system]] to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation<br />
[[File:Diagram showing stage 3A to 3C ovarian cancer CRUK 225.svg|alt=Diagram showing stage 3A to 3C ovarian cancer|thumb|'''Diagram showing stage 3A to 3C ovarian cancer''']]<br />
==Manufacturer==<br />
Abagovomab has been developed by the pharmaceutical company [[Menarini]]. <br />
<br />
==Clinical trials==<br />
A multicenter clinical trial, internationally known as MIMOSA is being studied.<br />
In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with [[paclitaxel]] and [[carboplatin]].<br />
* Unfortunately, [https://www.medpagetoday.org/meetingcoverage/esgo/28475?vpass=1 phase III of a trial] looking at potential benefit of Abagavomab in patients treated with [[ovarian cancer]] showed no benefit in preventing a remission.<br />
<br />
==Ovarian cancer==<br />
Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.<br />
<br />
==Also see==<br />
* [[Ovarian cancer]]<br />
* [[Experimental cancer drugs]]<br />
<br />
==External links==<br />
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221001/ Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer]<br />
* [https://clinicaltrials.gov/ct2/show/NCT00418574 Clinical trials]<br />
* [http://www.menarini.com/english/ricerca_sviluppo/abagovomab.htm Menarini page about abagovomab]<br />
* [http://www.mskcc.org/mskcc/html/2270.cfm?TAB=All&IRBNO=06-144&SelectedDisease=All Clinical trial MIMOSA]<br />
<br />
{{Monoclonals for tumors}}<br />
<br />
[[Category:Monoclonal antibodies for tumors]]<br />
[[Category:Experimental cancer drugs]]<br />
[[Category:Abandoned drugs]]<br />
<br />
{{Monoclonals for tumors}}<br />
{{stub}}<br />
[[Category:Monoclonal antibodies for tumors]]<br />
[[Category:Experimental cancer drugs]]<br />
[[Category:Abandoned drugs]]</div>Prab